The H3K27me3 demethylase, KDM6B, is induced by Epstein-Barr virus and over-expressed in Hodgkin's Lymphoma

School of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Oncogene (Impact Factor: 8.56). 01/2011; 30(17):2037-43. DOI: 10.1038/onc.2010.579
Source: PubMed

ABSTRACT There is now evidence for both increased and decreased activity of the enzymes controlling the methylation of lysine 27 on histone 3 (H3K27) in cancer. One of these enzymes, KDM6B formally known as JMJD3, a histone demethylase, which removes the trimethyl mark from H3K27, is required for the lineage commitment and terminal differentiation of neural stem cells and of keratinocytes. Our results suggest that KDM6B may also have a role in antigen-driven B-cell differentiation. KDM6B expression increases in B-cell subsets with increasing stage of differentiation, and gene expression profiling shows that KDM6B transcriptional targets in germinal centre B (GC B) cells are significantly enriched for those differentially expressed during memory and plasma cell differentiation. Our results also suggest that aberrant expression of KDM6B may contribute to the pathogenesis of Hodgkin's Lymphoma (HL), an Epstein-Barr virus (EBV) associated malignancy. KDM6B is over-expressed in primary HL and induced by the EBV oncogene, latent membrane protein (LMP1) in GC B cells, the presumptive progenitors of HL. Consistent with these observations, we found that KDM6B transcriptional targets in GC B cells are enriched for genes differentially expressed in HL, and that KDM6B depletion can restore the tri-methylation of H3K27 on these genes.

Download full-text


Available from: Martina Vockerodt, Apr 03, 2014
  • Source
    • "Because of the redundant activity of EZH1 and EZH2 (Shen et al. 2009; Ezhkova et al. 2011; Mochizuki-Kashio et al. 2011), interference with both enzymes may prove synergistic. JMJD3 was found to be overexpressed in cases of Hodgkin's lymphoma and T-ALL and is associated with the loss of H3K27me3 at derepressed target genes that may contribute to pathogenesis (Anderton et al. 2011; Simon et al. 2012). Finally, depletion of UTX was recently reported to severely impair proliferation of human leukemia cell lines (Liu et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the April 1, 2012, issue of Genes & Development, Simon and colleagues (pp. 651-656) demonstrated that the disruption of Ezh2 in mice is sufficient to cause T-acute lymphoblastic leukemia (T-ALL). Moreover, in concert with concurrent studies, the authors revealed that similar mechanisms are involved in human T-ALL. These data contrast with previous findings showing that increased EZH2 activity promotes cancer.
    Genes & development 04/2012; 26(8):751-5. DOI:10.1101/gad.191163.112 · 12.64 Impact Factor
  • Source
    • "Indeed, downregulation of KDM6B expression levels was found in various hematological malignancies . In contrast, others have reported overexpression of KDM6B in Hodgkin's lymphoma and prostate cancer progression (Anderton et al., 2011; Xiang et al., 2007a) suggesting that KDM6B may have cell-type-specific substrates, which require either gain-or lossof-function to provide a proliferative selective advantage during tumorigenesis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Resistance of cancer cells to chemotherapeutics and emerging targeted drugs is a devastating problem in the treatment of cancer patients. Multiple mechanisms contribute to drug resistance such as increased drug efflux, altered drug metabolism, secondary mutations in drug targets, and activation of downstream or parallel signal transduction pathways. The rapid kinetics, the reversibility of acquired drug resistance and the absence of genetic mutations suggest an epigenetic basis for drug insensitivity. Similar to the cellular variance seen in the human body, epigenetic mechanisms, through reversible histone modifications and DNA methylation patterns, generate a variety of transcriptional states resulting in a dynamic heterogeneous tumor cell population. Consequently, epigenomes favoring survival in the presence of a drug by aberrant transcription of drug transporters, DNA-repair enzymes and pro-apoptotic factors render cytotoxic and targeted drugs ineffective and allow selection of rare drug-resistant tumor cells. Recent advances in charting cancer genomes indeed strongly indicate a role for epigenetic regulators in driving cancer, which may result in the acquisition of additional (epi)genetic modifications leading to drug resistance. These observations have important clinical consequences as they provide an opportunity for "epigenetic drugs" to change reversible drug-resistance-associated epigenomes to prevent or reverse non-responsiveness to anti-cancer drugs.
    Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy 02/2012; 15(1-2):21-38. DOI:10.1016/j.drup.2012.01.008 · 8.82 Impact Factor
  • Source
    • "It has been suggested that aberrant expression of KDM6B stimulated by LMP1 may contribute to the pathogenesis of HL. Moreover, the authors suggest that the changes in the distribution of the H3K27me3 mark, along with the dynamics of DNA methylation on early viral promoters, might also play a role in the latent/lytic switch (Anderton et al. 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: About 15-20% of human cancers worldwide have viral etiology. Emerging data clearly indicate that several human DNA and RNA viruses, such as human papillomavirus, Epstein-Barr virus, Kaposi's sarcoma-associated herpesvirus, hepatitis B virus, hepatitis C virus, and human T-cell lymphotropic virus, contribute to cancer development. Human tumor-associated viruses have evolved multiple molecular mechanisms to disrupt specific cellular pathways to facilitate aberrant replication. Although oncogenic viruses belong to different families, their strategies in human cancer development show many similarities and involve viral-encoded oncoproteins targeting the key cellular proteins that regulate cell growth. Recent studies show that virus and host interactions also occur at the epigenetic level. In this review, we summarize the published information related to the interactions between viral proteins and epigenetic machinery which lead to alterations in the epigenetic landscape of the cell contributing to carcinogenesis.
    Clinical Epigenetics 08/2011; 2(2):233-47. DOI:10.1007/s13148-011-0026-6 · 6.22 Impact Factor
Show more